NotableTrial status: Completed to Terminatedv6Show 9 more changesShow less
Results first posted: Feb 24, 2026
Primary endpoint revised
Sponsor's reason: Low enrollment
Primary completion date: Jan 2008 to Mar 2008
Study completion date: Jul 2008 to Apr 2008
Interventions: perfluorocarbon emulsion (Oxycyte) infusion (Drug) to Oxycyte (Drug)
Secondary endpoints shortened, about 29 words
Study arms: 0 to 1
Collaborators shortened, about 3 words
MinorInterventions: Oxycyte infusion (Drug) to perfluorocarbon emulsion (Oxycyte) infusion (Drug)
Study title shortened, about 3 words
v5
MinorStudy title expanded, about 2 wordsv4
MinorTrial status: Recruiting to Completedv3Show 4 more changesShow less
Enrollment target: 8 to 9
Primary completion date: Jan 2008
Study completion date: Oct 2006 to Jul 2008
Site details revised
Re-verified, no change to tracked fieldsv2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in better brain oxygen consumption, less cell death, and better functional outcome. This study will test the hypothesis that Oxycyte is an effective way to increase brain oxygen levels in severe head injury.